黑色素瘤免疫相关性不良反应预测生物标志物  

Predictive Biomarkers for Immune-related Adverse Events in Melanoma

作　　者：于鑫 刘梦洁 郭卉[2,3,4,5] 姜丽丽 YU Xin;LIU Mengjie;GUO Hui;JIANG Lili(Department of Medical Oncology,the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710061,China;Phase I Clinical Trial Research Ward,the Second Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710004,China;Department of Medical Oncology,the Second Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710004,China;Key Laboratory of Environment and Genes Related to Diseases,Xi′an Jiaotong University,Ministry of Education of China,Xi′an 710061,China;Bioinspired Engineering and Biomechanics Center,Xi′an Jiaotong University,Ministry of Education of China,Xi′an 710049,China)

机构地区：[1]西安交通大学第一附属医院肿瘤内科,陕西西安710061 [2]西安交通大学第二附属医院Ⅰ期临床试验研究病房,陕西西安710004 [3]西安交通大学第二附属医院肿瘤内科,陕西西安710004 [4]西安交通大学环境基因相关疾病教育部重点实验室,陕西西安710061 [5]西安交通大学教务部仿生工程与生物力学中心,陕西西安710049

出　　处：《皮肤科学通报》2025年第1期1-6,共6页Dermatology Bulletin

摘　　要：黑色素瘤是恶性程度最高的皮肤肿瘤,具有高度侵袭性和转移性,对人类生命健康造成严重威胁。随着对黑色素瘤免疫微环境的深入探究,免疫检查点抑制剂(ICIs)已成为黑色素瘤治疗的重要手段,显著延长了黑素瘤患者的生存时间。ICIs在改善肿瘤局部微环境的同时,对T细胞功能的过度激活也会导致一系列炎症性不良事件,即免疫相关不良反应(irAEs)。这些不良反应会累及全身各器官和系统,并可能发生在免疫治疗的任何阶段,甚至会危及生命。因此,早期识别irAEs至关重要。本文将回顾生物标志物预测黑色素瘤irAEs的最新进展,旨在帮助临床医生评估药物风险并预警不良反应。Melanoma is the most malignant skin tumor,characterized by high invasiveness and metastasis,posing a serious threat to human health.As the immune microenvironment of melanoma is explored in depth,ICIs have become crucial in treating melanoma,significantly extending patients′survival.While ICIs improve the local tumor microenvironment,the excessive activation of T cell function can also lead to a series of inflammatory adverse events,namely irAEs.These adverse events can involve various organs and systems throughout the body and may occur at any stage of immunotherapy,and may even be life-threatening.Therefore,the early identification of irAEs is of crucial importance.This article will review the latest progress of predictive biomarkers for melanoma irAEs,aiming to assist clinicians in assessing drug risks and providing early warnings of adverse reactions.

关 键 词：黑色素瘤 免疫检查点抑制剂 免疫相关不良反应 预测生物标志物 

分 类 号：R739.5[医药卫生—肿瘤] R751[医药卫生—临床医学]